1. Clinical & Scientific Overview
Meropenem + Vaborbactam (TIP-MED-000535, Reference Code [R-16]) is classified under
Reserve Antimicrobials (WHO AWaRe Reserve) as a Carbapenem + Cyclic Boronic Acid Beta-Lactamase Inhibitor.
Within the Indian regulatory and compendial framework, it is governed under Schedule H1 Reserve Antibiotic.
Vabomere (Hospital Reserve Import / Special Access), Merovab (Institutional Reserve Formulary)
Powder for IV Infusion: Meropenem 1 g + Vaborbactam 1 g (2 g vial)
Statutory Restriction, High-Alert & Dispensing Safeguards
Indian Regulatory & Statutory Control Basis: Schedule H1 Reserve Antibiotic
High-Alert Clinical Risk, Dependence & Narrow Therapeutic Index Warnings: Inactive against Class B metallo-beta-lactamases (NDM, VIM, IMP) and Class D OXA-48; valproic acid co-administration precipitously drops serum valproate concentrations, triggering breakthrough seizures.
Mandatory Dispensing Register & Institutional Custody Protocol: Administer 4 g (2 g Meropenem + 2 g Vaborbactam) IV every 8 hours as a 3-hour extended infusion; adjust for eGFR <50 mL/min.
3. Mechanism of Action & Pharmacodynamics
Vaborbactam forms a covalent reversible bond with the catalytic serine of Class A KPC carbapenemases and Class C beta-lactamases, restoring Meropenem activity against KPC-producing Enterobacterales.
4. Therapeutic Indications & Evidence-Supported Uses
- Complicated urinary tract infections (including pyelonephritis) and CRE bacteraemia caused by KPC-producing Klebsiella pneumoniae
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Specialist-Supervised Educational Reference Summary: Dosing of Meropenem + Vaborbactam must be individualised by a qualified specialist according to clinical indication, organ function, and institutional protocol (Powder for IV Infusion: Meropenem 1 g + Vaborbactam 1 g (2 g vial)).
Administration & Meal Timing: Routes: Intravenous Infusion (over 3 hours). Administer 4 g (2 g Meropenem + 2 g Vaborbactam) IV every 8 hours as a 3-hour extended infusion; adjust for eGFR <50 mL/min.
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Exhibits carbapenem + cyclic boronic acid beta-lactamase inhibitor pharmacokinetic disposition; verify baseline renal and hepatic clearance and check for active or prolonged-half-life metabolites before repeat dosing.
Hepatic Phase I (CYP450) and/or Phase II conjugation or specific non-renal clearance as detailed in clinical warnings.
Verify eGFR / CrCl before initiation; see specific metabolite and renal clearance notes above.
Assess baseline Child-Pugh status and hepatic transaminases prior to therapy.
7. Contraindications, Precautions & High-Risk Warnings
- Known severe hypersensitivity to Meropenem + Vaborbactam or formulation excipients
- Unsupervised outpatient self-administration or dispensing without mandatory statutory prescription verification
- Specific clinical contraindications detailed under High-Alert Warnings & Statutory Restrictions
Key Clinical Precautions: Inactive against Class B metallo-beta-lactamases (NDM, VIM, IMP) and Class D OXA-48; valproic acid co-administration precipitously drops serum valproate concentrations, triggering breakthrough seizures.
8. Adverse Effects Profile
- Inactive against Class B metallo-beta-lactamases (NDM, VIM, IMP) and Class D OXA-48; valproic acid co-administration precipitously drops serum valproate concentrations, triggering breakthrough seizures.
- Dose-dependent target-organ pharmacodynamic effects requiring clinical observation
- Inactive against Class B metallo-beta-lactamases (NDM, VIM, IMP) and Class D OXA-48; valproic acid co-administration precipitously drops serum valproate concentrations, triggering breakthrough seizures.
- High-alert toxicity, dependence/diversion risk, or severe organ-specific adverse events if administered outside protocol
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Inactive against Class B metallo-beta-lactamases (NDM, VIM, IMP) and Class D OXA-48; valproic acid co-administration precipitously drops serum valproate concentrations, triggering breakthrough seizures.
- Review all concomitant CNS depressants, QTc-prolonging agents, nephrotoxins, or CYP450 modulators prior to dispensing.
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Administer 4 g (2 g Meropenem + 2 g Vaborbactam) IV every 8 hours as a 3-hour extended infusion; adjust for eGFR <50 mL/min.
Pharmacist Patient Counselling Points:
- Administer 4 g (2 g Meropenem + 2 g Vaborbactam) IV every 8 hours as a 3-hour extended infusion; adjust for eGFR <50 mL/min.
- Must be used strictly under direct medical supervision; never share prescription medicines or alter the prescribed dose.
Storage, Stability & Dispensing Safeguards: Administer 4 g (2 g Meropenem + 2 g Vaborbactam) IV every 8 hours as a 3-hour extended infusion; adjust for eGFR <50 mL/min.
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Drugs and Cosmetics Act, 1940 & Rules, 1945 (Schedule H / H1 / X); NDPS Act, 1985 & Essential Narcotic Drugs (END) Notification; Indian Pharmacopoeia (IP) & National Formulary of India (NFI).
Official Verification Portals: CDSCO — Drugs & Cosmetics Act and Rules (Schedules H, H1, X) • Department of Revenue — Narcotic Drugs and Psychotropic Substances (NDPS) Act • Indian Pharmacopoeia Commission (IPC) — National Formulary of India
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [R-17] Cefiderocol — Siderophore Cephalosporin ('Trojan Horse' Reserve Antibiotic)
- [R-18] Tedizolid Phosphate — Second-Generation Oxazolidinone Reserve Antibiotic
- [R-19] Oritavancin Diphosphate — Long-Acting Lipoglycopeptide Reserve Antibiotic
- [R-20] Dalbavancin Hydrochloride — Long-Acting Semisynthetic Lipoglycopeptide Antibiotic
